Skip to main content
Clinical Trials/JPRN-UMIN000026791
JPRN-UMIN000026791
Recruiting
未知

A prospective Randomized study comparing the effects of Empagliflozin versus Sitagliptin on Intra hepatic lipid content and hepatic insulin resistance in type 2 diabetes patients / Resistance study

Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Toho University Omori Medical Center0 sites44 target enrollmentMarch 30, 2017

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Toho University Omori Medical Center
Enrollment
44
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 30, 2017
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Toho University Omori Medical Center

Eligibility Criteria

Inclusion Criteria

  • Patients who meet all of the following criteria are included in this study.
  • 1\. Type 2 diabetic patients with HbA1c below 10% at the time of consenting
  • 2\. Female and male patients are 20 years old or older and younger than 75 years old
  • 3\. Patients who can take liver biopsy for the purpose of evaluation or diagnosis of non\-alcohol fatty liver disease
  • 4\. Patients with BMI 22 kg/m2 or higher
  • 5\. Patients who can provide their written consent for participation of this study

Exclusion Criteria

  • Patients who fall into any of the following criteria are excluded from participating in the study.
  • 1\. Patients with type 1 diabetes or secondary diabetes
  • 2\. Patients with BMI lower than 22 kg/m2
  • 3\. Patients with moderate to severe renal function disease or at the final stage of renal failure (eGFR lower than 45 mL/min/1\.73 m2\)
  • 4\. Patients who had stroke or cerebral infarction within 12 weeks before giving their consent
  • 5\. Patients with any medical history of myocardial infarction, angina pectoris, or currently with atrial fibrillation
  • 6\. Patients with any infectious disease
  • 7\. Patients with malignancy (However, those who have completed treatment and/or show no redevelopment of malignancy, as well as manifest some degree of remission can be considered to be participants of this study)
  • 8\. Patients with connective tissue disease (However, those T2DM patients who have treated with prednisolone 5 mg or less and show stable conditions can be considered to be participants of this study)
  • 9\. Patients with hepatocirrhosis

Outcomes

Primary Outcomes

Not specified

Similar Trials